We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.
On January 15, Goldman Sachs raised its price target on TG Therapeutics, Inc. (NASDAQ:TGTX) to $39 from $37 while maintaining a Neutral rating. The firm expects the stock to trade higher following the company’s disclosure of 2026 revenue guidance of $875 million to $900 million and noted that Phase 3 enrollment for the subcutaneous formulation of BRIUMVI is progressing ahead of expectations.
During its Q3 2025 earnings call, TG Therapeutics, Inc. (NASDAQ:TGTX) reported total revenue of $161.7 million, representing a 93% increase year over year and a 15% increase sequentially. U.S. BRIUMVI net sales reached approximately $153 million for the quarter, exceeding both internal targets and Street expectations. Management emphasized continued financial discipline despite accelerating commercial momentum, with a focus on sustaining long-term growth while maintaining profitability. The company reported GAAP net income of $390.9 million for the quarter, reflecting strong operating leverage as BRIUMVI adoption expands.
TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company focused on developing therapies for autoimmune diseases, particularly multiple sclerosis. The company was founded in 1993 and is headquartered in Morrisville, North Carolina, and is among the 10 best long term healthcare stocks to buy.
While we acknowledge the potential of TGTX as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy
Disclosure: None.
